News Information
The research and development achievements of the anti-liver cancer traditional Chinese medicine - Sanjie Pian have been included in the "National Science and Technology Achievements Database."
Release time:
2022-04-14
In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review by the Ministry of Science and Technology, and the research and development results were included in the national scientific and technological achievements database.
2021 Anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review of the Ministry of Science and Technology -Its technology has reached the advanced level in the country, and the research and development results have been included in the national science and technology achievement database (No. 6012021Y0389). It was publicly announced in March 2022 on the National Science and Technology Achievement Registration Work Platform (National Science Network).
Anti-liver cancer traditional Chinese medicine - Sanjie Pian, with the national drug approval number, is a patented product exclusively developed and produced by Zhuhai Miditech Biopharmaceutical Co., Ltd. The emergence of Sanjie Pian has brought hope to patients with liver cancer and cirrhosis. Sanjie Pian effectively prevents the recurrence and metastasis of liver cancer, while also reducing alpha-fetoprotein (which can prevent and stop the transformation of hepatitis B to liver cancer) and alleviating pain. It has an inhibitory effect on the growth of primary liver cancer and, when combined with interventional chemotherapy, can significantly improve clinical efficacy. The combination of traditional Chinese medicine Sanjie Pian + Beiqinglong Yi decoction + interventional chemotherapy for the treatment of liver cancer and cirrhosis has achieved good clinical results. We are currently applying for a national project on the integration of traditional Chinese and Western medicine; Sanjie Pian + Beiqinglong Yi + chemotherapy has also achieved good clinical results for pancreatic cancer; unexpected effects have been observed in patients with pancreatic cancer metastasizing to liver cancer (secondary liver cancer); the combination of Sanjie Pian + PD1 for the treatment of liver cancer is also in the process of applying for a national project on the integration of traditional Chinese and Western medicine. Professor Zheng Yongqi from Yale University in the United States used a classic traditional Chinese medicine formula + PD1 combination therapy to make all tumors in mice disappear, setting a model for this project application.
China is a major country for hepatitis B, with the incidence and mortality rates of liver cancer ranking first in the world. There are 450 million chronic liver disease patients in China. To achieve the goal of a healthy China by 2030, we must address the rehabilitation of 450 million chronic liver disease patients. Sanjie Pian is precisely the best choice to achieve the goal of a 'healthy China, cancer-free China'.
Related Information
Traditional Chinese Medicine for Liver Cancer and Liver Cirrhosis - Sanjie Pian, safeguarding 447 million chronic liver disease patients.
2022Year4Month15to21The day is the28first National Cancer Prevention and Control Publicity Week
In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review by the Ministry of Science and Technology, achieving a level of technological advancement that is considered leading in the country. The research and development results have been included in the National Science and Technology Achievements Database (No. 6012021Y0389). It was publicly announced on the National Science and Technology Achievements Registration Work Platform (Guokewang) in March 2022.
WeChat Subscription
Website mobile
Links:
Zhuhai Municipal Government
Guangdong Provincial Drug Administration
National Medical Products Administration
Address: Office Building Service Hotline, 150 Gate Road, Sanzao Town, Jinwan District, Zhuhai City:+86756-6331366